<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672852</url>
  </required_header>
  <id_info>
    <org_study_id>M15-992</org_study_id>
    <secondary_id>2014-005102-38</secondary_id>
    <secondary_id>1311.4</secondary_id>
    <nct_id>NCT02672852</nct_id>
  </id_info>
  <brief_title>BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment</brief_title>
  <official_title>BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a multinational, multicenter, randomized, double-blind, placebo controlled study
      with randomized withdrawal and retreatment, evaluating the safety and efficacy of
      risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque
      psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A1, eligible participants were randomized at Baseline at a ratio of 4:1, stratified
      by weight and prior exposure to tumor necrosis factor antagonists to receive double-blind
      (DB) risankizumab 150 mg or placebo at Weeks 0 and 4. In Part A2, participants randomized at
      Baseline to receive DB placebo then received risankizumab 150 mg at Weeks 16 (Part A2) and at
      Week 28 and every 12 weeks up to 88 weeks (Part B); participants randomized to risankizumab
      150 mg continued to receive risankizumab 150 mg at Week 16. Participants who received
      risankizumab in Part A and were nonresponders (sPGA &gt;2) at Week 28 received risankizumab 150
      mg at Week 28 and every 12 weeks up to 88 weeks (Part B). In Part B, participants who
      received risankizumab in Part A and were responders (sPGA ≤2) at Week 28, were rerandomized
      at a ratio of 1:2 to receive DB risankizumab 150 mg or placebo at Week 28 and every 12 weeks
      up to 88 weeks (Part B). Starting at Week 32, rerandomized participants who reached relapse
      (defined as sPGA ≥3) were switched to risankizumab 150 mg every 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2016</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">August 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Non-responder imputation (NRI) was used for missing data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an sPGA Score of Clear at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The DLQI is a 10-question questionnaire that asks the participant to evaluate the degree that psoriasis has affected their quality of life in the last week and includes 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment). Responses to each domain are not relevant (0), not at all (0), a little (1), a lot (2), and very much (3). The DLQI is calculated by summing the scores of the questions and ranges from 1 to 30, where 0-1 = no effect on patient's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on patient's life. The higher the score, the more the quality of life is impaired. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">507</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Risankizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risankizumab</intervention_name>
    <description>Risankizumab administered by subcutaneous injection</description>
    <arm_group_label>Risankizumab</arm_group_label>
    <other_name>BI 655066</other_name>
    <other_name>ABBV-066</other_name>
    <other_name>SKYRIZI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for risankizumab administered by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female participants. Woman of childbearing potential must be ready and willing
             to use highly effective methods of birth control per ICH M3 (R2) that result in a low
             failure rate of less than 1 percent per year when used consistently and correctly.

          -  Age ≥18 years at screening

          -  Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) at
             least 6 months before the first administration of study drug. Duration of diagnosis
             may be reported by the participant.

          -  Have stable moderate to severe chronic plaque psoriasis with or without psoriatic
             arthritis at both Screening and Baseline (Randomization); Have an involved body
             surface area (BSA) ≥ 10% and Have a Psoriasis Area and Severity Index (PASI) ≥ 12 and
             Have a static Physician Global Assessment (sPGA) score of ≥ 3.

          -  Must be a candidate for systemic therapy or phototherapy for psoriasis treatment, as
             assessed by the investigator

          -  Signed and dated written informed consent prior to admission to the study and
             performance of any study procedures in accordance with Good Clinical Practice (GCP)
             and local legislation

        Exclusion criteria:

          -  Participants with nonplaque forms of psoriasis (including guttate, erythrodermic, or
             pustular); current drug-induced psoriasis (including a new onset of psoriasis or an
             exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium);
             active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that
             might confound trial evaluations according to the investigators judgment.

          -  Previous exposure to ABBV-066

          -  Currently enrolled in another investigational study or less than 30 days (from
             screening) since completing another investigational study

          -  Use of any restricted medication as noted or any drug considered likely to interfere
             with the safe conduct of the study.

          -  Major surgery performed within 12 weeks prior to randomization or planned within 12
             months after screening (e.g., hip replacement, removal aneurysm, stomach ligation).

          -  Known chronic or relevant acute infections such as active tuberculosis, human
             immunodeficiency virus (HIV), or viral hepatitis

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma or squamous cell
             carcinoma of the skin or in situ carcinoma of uterine cervix

          -  Evidence of a current or previous disease (including chronic alcohol or drug abuse),
             medical condition other than psoriasis, surgical procedure (i.e., organ transplant),
             medical examination finding (including vital signs and electrocardiogram [ECG]), or
             laboratory value at the screening visit outside the reference range that in the
             opinion of the Investigator, is clinically significant and would make the study
             participant unable to adhere to the protocol or to complete the trial, compromise the
             safety of the patient, or compromise the quality of the data.

          -  History of allergy/hypersensitivity to a systemically administered biologic agent or
             its excipients

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial

          -  Previous enrolment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <results_first_submitted>May 3, 2019</results_first_submitted>
  <results_first_submitted_qc>May 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2019</results_first_posted>
  <disposition_first_submitted>October 31, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 31, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 6, 2017</disposition_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-066</keyword>
  <keyword>BI 655066</keyword>
  <keyword>risankizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT02672852/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT02672852/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part A1: double-blind (DB) risankizumab or placebo (Weeks 0,4). Part A2 (Week 16) DB placebo to DB risankizumab; risankizumab continued risankizumab. Part B (Week 28) risankizumab responders rerandomized to DB risankizumab/placebo; risankizumab nonresponders continued risankizumab. Week 32: rerandomized relapsed switch risankizumab.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Part A1)</title>
          <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
        </group>
        <group group_id="P2">
          <title>Risankizumab (Part A1)</title>
          <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Risankizumab Part A2/Part B</title>
          <description>Participants randomized at Baseline to receive double-blind (DB) placebo then received DB risankizumab 150 mg at Weeks 16 (Part A2) and at Week 28 and every 12 weeks up to 88 weeks (Part B).</description>
        </group>
        <group group_id="P4">
          <title>Risankizumab/Risankizumab Part A2</title>
          <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab then received DB risankizumab 150 mg at Weeks 16 (Part A2).</description>
        </group>
        <group group_id="P5">
          <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
          <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
        </group>
        <group group_id="P6">
          <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
          <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
        </group>
        <group group_id="P7">
          <title>Risankizumab/Risankizumab Part B (Nonresponders)</title>
          <description>Participants who received risankizumab in Part A and were nonresponders (sPGA ≥2) at Week 28 received risankizumab 150 mg at Week 28 and every 12 weeks up to 88 weeks (Part B).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="407"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Worsening</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants that completed Part A1 continued on to Part A2.</participants>
                <participants group_id="P2" count="0">Participants that completed Part A1 continued on to Part A2.</participants>
                <participants group_id="P3" count="93">Participants that completed Part A1 continued on to Part A2.</participants>
                <participants group_id="P4" count="403">Participants that completed Part A1 continued on to Part A2.</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="399"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not entered in Part B</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">Participants that completed Part A2 continued on to Part B.</participants>
                <participants group_id="P4" count="0">Participants that completed Part A2 continued on to Part B.</participants>
                <participants group_id="P5" count="225">Participants that completed Part A2 continued on to Part B.</participants>
                <participants group_id="P6" count="111">Participants that completed Part A2 continued on to Part B.</participants>
                <participants group_id="P7" count="63">Participants that completed Part A2 continued on to Part B.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="209"/>
                <participants group_id="P6" count="100"/>
                <participants group_id="P7" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening pre-existing condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Population in Part A1 (ITT_A1): All participants who were randomized at Baseline</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Part A1)</title>
          <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
        </group>
        <group group_id="B2">
          <title>Risankizumab (Part A1)</title>
          <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="407"/>
            <count group_id="B3" value="507"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="13.78"/>
                    <measurement group_id="B2" value="49.6" spread="13.17"/>
                    <measurement group_id="B3" value="49.2" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Non-responder imputation (NRI) was used for missing data.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Intent to treat (ITT) Population in Part A1(ITT_A1): all participants who were randomized at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Non-responder imputation (NRI) was used for missing data.</description>
          <population>Intent to treat (ITT) Population in Part A1(ITT_A1): all participants who were randomized at Baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the Cochran-Mantel-Haenszel (CMH) test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>70.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.7</ci_lower_limit>
            <ci_upper_limit>76.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT Population in Part A1(ITT_A1)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT Population in Part A1(ITT_A1)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>76.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.4</ci_lower_limit>
            <ci_upper_limit>82.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT Population in Part B for re-randomized participants (ITT_B_R): All participants who were randomized to Arm 1 at Baseline and re randomized at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT Population in Part B for re-randomized participants (ITT_B_R): All participants who were randomized to Arm 1 at Baseline and re randomized at Week 28.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3"/>
                    <measurement group_id="O2" value="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>25.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.3</ci_lower_limit>
            <ci_upper_limit>34.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT Population in Part A1 (ITT_A1)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT Population in Part A1 (ITT_A1)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>80.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.5</ci_lower_limit>
            <ci_upper_limit>86.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT Population in Part A1 (ITT_A1)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT Population in Part A1 (ITT_A1)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>45.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.3</ci_lower_limit>
            <ci_upper_limit>50.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an sPGA Score of Clear at Week 16</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT Population in Part A1 (ITT_A1)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an sPGA Score of Clear at Week 16</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT Population in Part A1 (ITT_A1)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>44.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.5</ci_lower_limit>
            <ci_upper_limit>50.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16</title>
        <description>The DLQI is a 10-question questionnaire that asks the participant to evaluate the degree that psoriasis has affected their quality of life in the last week and includes 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment). Responses to each domain are not relevant (0), not at all (0), a little (1), a lot (2), and very much (3). The DLQI is calculated by summing the scores of the questions and ranges from 1 to 30, where 0-1 = no effect on patient's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on patient's life. The higher the score, the more the quality of life is impaired. NRI was used for missing data.</description>
        <time_frame>Week 16</time_frame>
        <population>ITT Population in Part A1 (ITT_A1)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab (Part A1)</title>
            <description>Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16</title>
          <description>The DLQI is a 10-question questionnaire that asks the participant to evaluate the degree that psoriasis has affected their quality of life in the last week and includes 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment). Responses to each domain are not relevant (0), not at all (0), a little (1), a lot (2), and very much (3). The DLQI is calculated by summing the scores of the questions and ranges from 1 to 30, where 0-1 = no effect on patient's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on patient's life. The higher the score, the more the quality of life is impaired. NRI was used for missing data.</description>
          <population>ITT Population in Part A1 (ITT_A1)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>62.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.4</ci_lower_limit>
            <ci_upper_limit>67.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104</title>
        <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
        <time_frame>Week 104</time_frame>
        <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
        <group_list>
          <group group_id="O1">
            <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104</title>
          <description>The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean &gt;0, &lt;1.5; Mild (2) = mean ≥1.5, &lt;2.5; Moderate (3) = mean ≥2.5, &lt;3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.</description>
          <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>73.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.0</ci_lower_limit>
            <ci_upper_limit>81.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
        <group_list>
          <group group_id="O1">
            <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                    <measurement group_id="O2" value="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>21.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>28.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
        <group_list>
          <group group_id="O1">
            <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>33.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.0</ci_lower_limit>
            <ci_upper_limit>42.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52</title>
        <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
        <group_list>
          <group group_id="O1">
            <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
            <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52</title>
          <description>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</description>
          <population>ITT Population in Part B for re-randomized participants (ITT_B_R)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Across strata, P value was calculated from the CMH test adjusted for strata. Within each stratum, P value was calculated based on the chi-square test (or Fisher's exact test if ≥25% of the cells had expected cell count &lt;5).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percentage difference</param_type>
            <param_value>33.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.2</ci_lower_limit>
            <ci_upper_limit>44.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug (up to 103 weeks).</time_frame>
      <desc>TEAEs and TESAEs: defined as any adverse event (AE) or serious adverse event (SAE) with onset or worsening reported by participant from time to first dose of study drug administered within 15 weeks following discontinuation of risankizumab administration or, for AEs presented by study Part, from first dose in the study Part until prior to first dose in the subsequent study Part (Part A1=from Week 0 until prior to Week 16 dose; Part B=from Week 28 to 15 weeks after last dose at [up to Week 103]).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part A1)</title>
          <description>All participants randomized at Baseline to receive double-blind (DB) placebo at Weeks 0 and 4 (Part A1).</description>
        </group>
        <group group_id="E2">
          <title>Risankizumab (Part A1)</title>
          <description>All participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg at Weeks 0 and 4 (Part A1).</description>
        </group>
        <group group_id="E3">
          <title>Risankizumab/Placebo (Part B; Rerandomized Responders)</title>
          <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive placebo at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
        </group>
        <group group_id="E4">
          <title>Risankizumab/Risankizumab (Part B; Rerandomized Responders)</title>
          <description>Participants who received risankizumab in Part A and were responders (sPGA 0 or 1) at Week 28, and rerandomized to receive risankizumab 150 mg at Week 28 and every 12 weeks up to Week 88 (Part B).</description>
        </group>
        <group group_id="E5">
          <title>Any Risankizumab</title>
          <description>Participants who received at least one dose of risankizumab during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 21</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Benign familial pemphigus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Huntington's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Open globe injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Breast cancer stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 21</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="225"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="242" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="407"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" events="24" subjects_affected="22" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="407"/>
                <counts group_id="E3" events="53" subjects_affected="45" subjects_at_risk="225"/>
                <counts group_id="E4" events="36" subjects_affected="23" subjects_at_risk="111"/>
                <counts group_id="E5" events="170" subjects_affected="116" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="407"/>
                <counts group_id="E3" events="29" subjects_affected="23" subjects_at_risk="225"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E5" events="97" subjects_affected="77" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="407"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E5" events="37" subjects_affected="35" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" events="31" subjects_affected="28" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="407"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E5" events="47" subjects_affected="34" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

